FDA Approves Moderna’s mRNA Flu Vaccine for Adults 50 and Older
The U.S. Food and Drug Administration has approved Moderna's Mfluziva, a new mRNA flu vaccine, for adults aged 50 and older. This vaccine, which uses similar technology to mRNA COVID-19 vaccines, has shown higher effectiveness than standard flu shots in…
Tucson, AZ, September 22, 2026 —
Washington D.C. – The U.S. Food and Drug Administration (FDA) has granted approval for Moderna’s Mfluziva, a novel mRNA-based influenza vaccine. The vaccine is indicated for use in adults aged 50 years and older.
Mfluziva utilizes messenger RNA (mRNA) technology, the same scientific foundation employed in many of the COVID-19 vaccines developed by Moderna. This approval marks a significant step in vaccine development, bringing mRNA technology to routine influenza immunization for a specific adult demographic.
Clinical trials have indicated that Mfluziva demonstrated higher effectiveness compared to traditional, standard-dose flu shots. The specifics of the trial results, including the precise margin of increased effectiveness and the names of the trials, were not detailed in the available information. Furthermore, the timeline for the potential manufacturing speed advantage mentioned in the vaccine’s description was not provided.
The development of Mfluziva by Moderna aims to offer an alternative or enhanced option for seasonal flu vaccination. The broader implications of mRNA technology in vaccine manufacturing speed and adaptability are noted as a potential benefit.
Further details regarding the availability and rollout of Mfluziva are expected to be announced by Moderna.
Story summarized from the original created by Scripps News Group on www.kgun9.com, see more information here.